GGrantIndex
← Leaderboards

Timothy J. Triche

University Of Southern California

Google Scholar ↗PubMed ↗ORCID ↗
$21,258,785
Attributed
$27,355,437
Total exposure
9
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,355,437 · 9

By mechanism

U01$14,547,053 · 2
R01$3,403,254 · 1
RC2$2,862,111 · 1
R42$2,400,000 · 1
R44$2,152,772 · 1
P30$1,749,497 · 2

Top collaborators

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsTumorGene ExpressionCellsTissuesBaseSystemic TherapyProgramsResistanceResearch PersonnelGenesRhabdomyosarcomaMolecular ProfilingMolecularProtocols DocumentationDiagnosisResponseNovel TherapeuticsNucleic Acid ProbesHigh RiskCancer TherapyEvaluationFundingMicroarray Technology

Grant awards (33)

Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$1,000,000
R42 · FY2025 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$689,813
R01 · FY2025 · CA
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$1,000,000
R42 · FY2024 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$655,325
R01 · FY2024 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,022
R01 · FY2023 · CA
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)$400,000
R42 · FY2023 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$676,023
R01 · FY2022 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer$706,071
R01 · FY2021 · CA
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$892,769
R44 · FY2020 · CA
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$1,019,254
R44 · FY2019 · CA
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy$240,749
R44 · FY2018 · CA
Nanoparticle Delivery System for Ewing Sarcoma Treatment$240,750
R41 · FY2016 · CA
Translation of Predictive Cancer Biomarkers into Clinical Practice$1,308,910
RC2 · FY2010 · CA · contact PI
Microarray Core Facility$406,906
P30 · FY2010 · CA · contact PI
Diagnostic and Prognostic Sarcoma Signatures$1,731,711
U01 · FY2009 · CA · contact PI
Translation of Predictive Cancer Biomarkers into Clinical Practice$1,553,201
RC2 · FY2009 · CA · contact PI
Microarray Core Facility$412,693
P30 · FY2009 · CA · contact PI
Diagnostic and Prognostic Sarcoma Signatures$1,689,820
U01 · FY2008 · CA · contact PI
Microarray Core Facility$353,343
P30 · FY2008 · CA · contact PI
Diagnostic and Prognostic Sarcoma Signatures$1,657,644
U01 · FY2007 · CA · contact PI
Microarray Core Facility$397,328
P30 · FY2007 · CA · contact PI
Diagnostic and Prognostic Sarcoma Signatures$1,686,988
U01 · FY2006 · CA · contact PI
Microarray Core Facility$179,227
P30 · FY2006 · CA · contact PI
Diagnostic and Prognostic Sarcoma Signatures$1,730,668
U01 · FY2005 · CA
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE$982,242
U01 · FY2004 · CA
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE$1,184,946
U01 · FY2003 · CA
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE$1,747,375
U01 · FY2002 · CA
CORE--MICROARRAY$0
P30 · FY2002 · CA
CORE--MICROARRAY$0
P30 · FY2002 · CA
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE$1,421,115
U01 · FY2001 · CA
CORE--MICROARRAY$0
P30 · FY2001 · CA
CORE--MICROARRAY$0
P30 · FY2001 · CA
GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE$714,544
U01 · FY2000 · CA